Pfizer buys Amplyx to expand drug-resistant treatment portfolio

  29 April 2021

Pfizer Inc said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant “superbug” fungal infections in patients with compromised immune systems.

If approved, Amplyx’s lead drug fosmanogepix would be the first new class of antifungal treatments in 20 years. Terms of the deal were not disclosed.

Fungi, like bacteria, can develop the ability to defeat the drugs designed to kill them.

Further reading: WHTC
Author(s): Julie Steenhuysen
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed